

THE SYNTHESIS OF 15-DEOXY-9,11-(EPOXYIMINO)PROSTAGLANDINS-
POTENT THROMBOXANE SYNTHETASE INHIBITORS



G.L. Bundy* and D.C. Peterson
The Upjohn Company
Kalamazoo, Michigan

(Received in USA 19 September 1977; received in UK for publication 8 November 1977)

The central role of the prostaglandin endoperoxides PGG₂ and PGH₂¹ in arachidonic acid metabolism is becoming increasingly apparent. These unstable peroxides are the precursors not only for the classical prostaglandins¹ (PGE₂, PGF_{2α}, PGD₂), but also for a hydroxylated C-17 fatty acid (HHT), the thromboxanes² (TXA₂ and TXB₂) and the recently discovered prostacyclin³ (PGI₂). Current studies into the complex interactions between these various pathways in physiological systems have benefited from the availability of several chemically more stable endoperoxide analogs.⁴ These analogs, similar in shape and polarity to the endoperoxides, exhibit a biological activity profile reminiscent of the less stable endoperoxides themselves.⁵

Recently, we have found that 9α,11α-azoprosta-5Z,13E-dienoic acid 3⁶, which lacks the C-15 hydroxyl group of the natural prostaglandins and also most of the agonist activities typical of PGH₂⁵ and its analogs, is a potent inhibitor of the enzyme which converts PGH₂ into thromboxane A₂ in human platelets.⁶

We report herein the synthesis of two 15-deoxy prostaglandin endoperoxide analogs 1 and 2, in which the chemically unstable peroxide linkage of PGH₂ has been replaced with the more stable epoxyimino (-NH-O-) group. Like 15-deoxy azo analog 3, these cyclic O,N-disubstituted hydroxylamine derivatives do not exhibit the biological activities typical of PGH₂, but rather are potent inhibitors of the thromboxane A₂ synthetase in human platelets.⁷



The synthetic pathway to epoxyimino compounds 1 and 2, outlined in Figure I, begins in both cases with 15-deoxy-11β-PGF_{2β}, available in four steps and 53% overall yield from PGF_{2α} as described earlier.⁶ Taking advantage of the different steric environments of the C-9 and C-11 hydroxyls in 15-deoxy-11β-PGF_{2β} (4), conversion to the C-9 monotosylate 5 proceeded in 92% yield⁸





FIGURE I

(1.5 equiv of *p*-toluenesulfonyl chloride, pyridine, 0°, 4 days). That the regioselective tosylation had occurred at C-9 and not C-11 was inferred from several considerations. Inspection of molecular models indicates that the C-9 hydroxyl, trans to the adjacent side chain, is clearly the less hindered of the two. Analogous selectivity is observed in the silylation of 9 α ,11 α -prostaglandin diols, where reaction occurs preferentially at the hydroxyl trans to the adjacent side chain⁹ (in this case C-11). In addition, the minor product in the formation of 5, an isomeric hydroxytosylate isolated in 5% yield, was considerably more polar than 5 on thin layer chromatography. This increased polarity for the C-11 monotosylate by-product can be rationalized based on the greater accessibility of the C-9 hydroxyl for interaction with the silica.¹⁵

The monotosylate 5 was then treated with triphenylphosphine, *N*-hydroxyphthalimide and diethyl azodicarboxylate¹⁰ in tetrahydrofuran (15 min, 0°), thereby affording *N*-alkoxyphthalimide 6 (45% yield after chromatography; PHT = phthalimido). Deprotection of the masked O-alkylhydroxylamine 6 with hydrazine (5 equiv, methanol, 25°, 1 hr) yielded epoxyimino ester 7 directly (77%), via the hydroxylamine tosylate, which could be seen by tlc early in the hydrazinolysis but which was never isolated. Standard ester hydrolysis with aqueous methanolic potassium hydroxide gave the 11 α ,9 α -epoxyimino acid 1 in 90% yield: mp 53-54° (from 5% ether/hexane); r_f 0.39 (silica tlc plates, 50% ethyl acetate/hexane with 1% acetic acid); $\delta_{TMS}^{CDCl_3}$ 4.20 (CHO) and 3.65 ppm (CHN); mass spectrum of TMS derivative: M^+ 407.2832 (theoretical for C₂₃H₄₁SiNO₃: 407.2850).

The synthesis of 9 α ,11 α -epoxyimino derivative 2 (O and NH interchanged from 1) required blocking the C-9 hydroxyl group temporarily and converting the more hindered C-11 hydroxyl to a sulfonate ester. Attempted selective silylation of C-9 using *t*-butyldimethylsilyl chloride under standard conditions¹¹ proved surprisingly unsuccessful. Even at -60° (7 days), a statistical array of products was obtained including starting material, both monosilyl derivatives and the disilyl derivative. Selective silylation of 15-deoxy-11 β -PGF₂ β 4 could be achieved with trimethylsilyldiethyl amine¹², a sterically more discriminating silylating agent, yielding monosilyl derivative 8 (70% after rapid chromatographic purification).¹⁵ Subsequent conversion to the C-11 mesylate (methanesulfonyl chloride, triethylamine, methylene chloride, 10 min, 0°) and removal of the silyl group (methanolic citric acid, 10 min, 20°) proceeded in essentially quantitative yield. Then, following the same sequence as before, monomesylate 10 was transformed into *N*-alkoxyphthalimide 11 (66%; mp 62-63°) and finally 9 α ,11 α -epoxyimino derivative 12 and the corresponding acid 2: r_f 0.28 (silica plate, 50% ethyl acetate/hexane with 1% acetic acid) $\delta_{TMS}^{CDCl_3}$ 4.30 (CHO) and 3.55 ppm (CHN).

Epoxyimino derivatives 7 and 12 were further characterized by reduction of the N-O bond¹³



(zinc, acetic acid, 25°, 20 min) followed by acetylation (acetic anhydride, pyridine, 25°, 3 h), which afforded derivatives 13 (M^+ 435.2984) and 14 (M^+ 435.3003) respectively (theoretical for $C_{25}H_{41}NO_5$: 435.2984).

The epoxyimino derivatives 1 and 2 showed only very low levels of activity on rat blood pressure and gerbil colon. However, like 15-deoxy azo analog 3, the epoxyimino analogs 1 and 2 are both potent inhibitors of thromboxane synthetase from human platelets (active in the range of 10^{-5} to 10^{-6} M).⁷

In addition to providing biologically interesting analogs, the synthetic scheme in Figure 1 offers a generic solution to the problem of synthesizing cyclic O,N-disubstituted hydroxylamines, many of which are difficult to obtain by classical procedures.¹⁴

REFERENCES

1. M. Hamberg and B. Samuelsson, Proc. Natl. Acad. Sci. USA 70(3), 899 (1973).
2. M. Hamberg, J. Svensson and B. Samuelsson, *ibid.* 72, 2994 (1975).
3. S. Moncada, R. Gryglewski, S. Bunting and J. Vane, Nature 263, 663 (1976).
4. See for example: a. G.L. Bundy, Tetrahedron Lett. (24), 1957 (1975). b. E.J. Corey, K.C. Nicolaou, Y. Machida, C.L. Malmsten and B. Samuelsson, Proc. Natl. Acad. Sci. USA 72, 3355 (1975).
5. R. Gorman, J. Cyclic Nucleotide Res. 1, 1 (1975).
6. R. Gorman, G.L. Bundy, D.C. Peterson, F.F. Sun, O.V. Miller and F.A. Fitzpatrick, Proc. Nat'l Acad. Sci. USA 74 (9) 4007 (1977).
7. F.F. Sun, unpublished observation.
8. Structural assignments for the various synthetic intermediates were confirmed by infrared, proton magnetic resonance and mass spectroscopy on chromatographically homogeneous samples.
9. E.W. Yankee, U. Axen and G.L. Bundy, J. Am. Chem. Soc. 96, 5865 (1974).
10. E. Grochowski and J. Jurczak, Synthesis, 682 (1976).
11. E.J. Corey and A. Venkateswarlu, *ibid.* 94, 6190 (1972).
12. I. Weisz, K. Felfoldi and K. Kovacs, Acta Chim. Acad. Sci. Hung. 58, 189 (1968).
13. N. Nitsch and G. Kerze, Angew. Chem. 88, 801 (1976).
14. G. Just and L. Cutrone, Can. J. Chem. 54, 867 (1976) and references therein.
15. Independent chemical confirmation of the regiochemical assignments for hydroxytosylate 5 and hydroxymesylate 10 was provided by the following observations. The carboxylic acid corresponding to mesylate ester 10, upon treatment with triphenylphosphine and 2,2'-di-pyridyl disulfide and heating in dilute toluene solution at 100° for 6 hr, afforded the 1,9 β -lactone in 50% yield. [Method of E.J. Corey and K.C. Nicolaou, J. Am. Chem. Soc. 96, 5614 (1974)]. Under identical conditions, the carboxylic acid corresponding to tosylate ester 5 formed the activated pyridinethiol ester intermediate, but did not lactonize. Molecular models clearly show that lactonization with the 11 β -hydroxyl should be much more difficult than with the 9 β -hydroxyl, based on steric considerations.